No Data
Institutional Investors Have a Lot Riding on Relmada Therapeutics, Inc. (NASDAQ:RLMD) With 48% Ownership
Express News | CORRECTION: (Reported June 18, 2024) Relmada Therapeutics Announced Publication Of Results From The Phase 3 Reliance I Study of REL-1017 In The Journal Of Clinical Psychiatry
Earlier, Relmada Therapeutics Announced Publication Of Results From The Phase 3 Reliance I Study of REL-1017 In The Journal Of Clinical Psychiatry
Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the publication of REL-1017 clinical data from
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...
Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Keybanc rai
Relmada Therapeutics Price Target Cut to $2.00/Share From $3.00 by Goldman Sachs
Relmada Therapeutics Price Target Cut to $2.00/Share From $3.00 by Goldman Sachs